However, treatment of puromycin aminonucleoside nephropathy with a high dose of anti-TGF-β antibody produces no renoprotective effect [9], which is consistent with a recent finding that disruption of TGF-β type II receptor decreased renal fibrosis but enhanced renal inflammation [10]. Here, TGFB1 is linked to renal fibrosis.